Drugs / TCR-transduced lymphocytes
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| — | NCT05389514 | — | — | Providence Health & Services | Temporarily not available | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TCR-transduced lymphocytes | “Patient's T cells will be administered at a dose of between 1 x 10\^9 to 5.0 x 10\^10 TCR-transduced lymphocytes, which is a dose of genetically modified T cells that can be...” NCT05389514 ↗ |
| Route | Intravenous | “The cells are to be infused intravenously” NCT05389514 ↗ |
| Target | KRAS | “HLA-DRB1\*07:01-restricted KRAS G12V reactive T-cell receptors (TCR).” NCT05389514 ↗ |